Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF RXSIGHT, INC. (NASDAQ: RXST)

Grabar Law Office is investigating claims on behalf of shareholders of RxSight, Inc. (NASDAQ: RXST). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

RxSight, Inc. is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses (“LAL”) used in cataract surgery in the United States. The Company’s primary product is the RxSight system, which includes the LAL and a specially designed machine for delivering light to the eye, the Light Delivery Device (“LDD”).

According to a recently filed federal securities fraud class action Complaint, it is alleged RxSight, via certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors that: (1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 8, 2025, RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.” On this news, RxSight shares fell $4.84, or 37%, to a close of $7.95 per share on July 9, 2025.

WHAT YOU CAN DO NOW: If you purchased RxSight, Inc. (NASDAQ: RXST) shares prior to November 7, 2024, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If, alternatively, you purchased your shares between
November 7, 2024, and July 8, 2025, you can participate in the class action.

Attorney Advertising Disclaimer

Join This Action
Name*
First Last
Email Address*
Address*
Street Address City State / Province / Region ZIP / Postal Code
Phone*
Stock Name or Ticker
Number of Shares Purchased
Date(s) Shares Purchased
Purchase Price Per Share
Number of Shares Sold
Date(s) Shares Sold
Sale Price Per Share
Comments
Alternatively, you may upload your transactions using the upload button below or email them to jgrabar@grabarlaw.com. *
File
Drop files here or

Max. file size: 100 MB.
Consent*
By signing and clicking the Submit button below, I hereby execute the Retention Agreement and, upon execution of the Retention Agreement by Grabar Law Office, retain Grabar Law Office to make a demand and bring any ensuing lawsuit on my behalf pursuant to the terms set forth in the Retention Agreement, which is incorporated herein by reference.*
Please sign below using your mouse or touch-pad.*
Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.
Date of signing: *
Date of signing:*
MM slash DD slash YYYY
Name
This field is for validation purposes and should be left unchanged.

Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF RXSIGHT, INC. (NASDAQ: RXST)

Join This Action